Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 10/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 6/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.67 |
| ▸ | QPCT | Q16769 | 1/20 | 0.67 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.64 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024261 | 0.90 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.88 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL11705239 | 0.86 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6057476 | 0.84 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2529997 | 0.84 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL570342 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL11499390 | 0.82 | CYP19A1 (0.70) | CYP11B1CYP11B2CYP19A1TBXAS1ADRA2C | |
| SCHEMBL2729830 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6986190 | 0.81 | HMOX1 (0.79) | CYP11B1CYP11B2CYP19A1TBXAS1HMOX1 | |
| SCHEMBL17407550 | 0.81 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333581-B | Synthetic method of ozagrel sodium | 北京哈三联科技有限责任公司 | 2021-10-15 | — | — | CN | claimed |
| CN-111333581-A | Synthetic method of ozagrel sodium | 北京哈三联科技有限责任公司 | 2020-06-26 | — | — | CN | claimed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-117916229-A | Novel selective angiotensin II compounds | 维科尔药物公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023281271-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| CN-111333581-B | Synthetic method of ozagrel sodium | 北京哈三联科技有限责任公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
| EP-1395566-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096883-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| EP-0891333-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036875-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0664802-A1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | CYP11B1 1082/4885CYP11B2 950/4885CYP19A1 2703/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CYP11B1 4229/4885CYP11B2 4345/4885CYP19A1 4700/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | CYP11B1 4229/4885CYP11B2 4345/4885CYP19A1 4700/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CYP11B1 4229/4885CYP11B2 4345/4885CYP19A1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.